The University of Sydney
Project title: Local Regulation of Inflammation for the Treatment of Peripheral Arterial Disease
Peripheral artery disease (PAD) is the most common manifestation of cardiovascular disease in the lower limbs. Advanced PAD severely diminishes quality of life, affecting patients' mobility and, in its most severe form leads to limb amputation and death. In diabetic patients, where advanced PAD often manifests below the knee, the downward spiral of chronic limb-threatening ischemia, tissue loss and amputation, is intractable. Current therapies have major drawbacks that limit their effectiveness.
We have assembled a team of bioengineers, vascular biologists, and clinicians to develop is an injectable treatment for PAD that leaves no permanent device behind. We have developed: a proprietary nanoparticle platform that is easy to functionalise with bioactive agents that increases local drug retention in the vasculature; a new paradigm for the 'switching off' of local inflammation; and a specialised tri-balloon catheter we designed that will target delivery of our nanotherapy to sites of disease.
Working closely with our partners Sydney Local Health Districts and Sydney-based medical technology company Endoluminal Sciences, this grant will facilitate the advancement of our approach towards commercialisation of a therapy that stands to have significant impact on the treatment of PAD.
TTRA Project Round: One
State: New South Wales
Project Partners:
- Sydney Local Health District
- Endoluminal Sciences
Funding:
- TTRA: $739,128
- Industry Contribution: $60,292.20 cash, $696,600 in-kind
Duration: February 2022 – March 2024
Website: www.sydney.edu.au | LinkedIn: University of Sydney
Twitter: @docswise @Sydney_Uni @SydneyLHD @SydneyNano